As ASCT2 transports glutamine for tumor consumption, inhibiting ASCT2 induces apoptosis and exhibits anti-cancer activity in acute myeloid leukemia [18], gastric cancer [19], prostate cancer [20], and triple-negative breast cancer [21]. Here, SLC1A5 is linked to neoplasm.